Thus, whereas immunohistochemical analysis showed no significant correlation of MAL protein expression in breast tumors with clinical-pathological variables or the disease-free survival period when patients received chemotherapy, a separate analysis of patients who did not receive chemotherapy showed that survival in cases of the loss of MAL expression may have been favored by adjuvant therapy [200]. The gene discussed is MAL; the disease is breast neoplasm.